IOVS Brain
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2004;45:4247-4250.)
© 2004 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.04-0591
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krishnakumar, S.
Right arrow Articles by Ren-Heidenreich, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krishnakumar, S.
Right arrow Articles by Ren-Heidenreich, L.

EpCAM Expression in Retinoblastoma: A Novel Molecular Target for Therapy

Subramanian Krishnakumar,1 Adithi Mohan,1 Kandalam Mallikarjuna,1 Nalini Venkatesan,1 Jyotirmay Biswas,1 Mahesh Palanivelu Shanmugam,2 and Lifen Ren-Heidenreich3

1From the Department of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, India; the 2Department of Ocular Oncology, Medical Research Foundation, Sankara Nethralaya, Chennai, India; and the 3Molecular Immunology Laboratory, Adele R. DeCof Cancer Center, Roger Williams Hospital, Providence, Rhode Island.

PURPOSE. This study was conducted to investigate the potential of targeting epithelial cell adhesion molecules (EpCAMs) in the treatment of retinoblastoma. It was first determined whether EpCAM is expressed in retinoblastoma and then whether EpCAM reactivity correlates with tumor aggressiveness.

METHODS. EpCAM reactivity was evaluated by immunohistochemistry in 43 retinoblastoma specimens from 43 patients, by using the monoclonal antibody GA733.2. The tumors were divided into two groups. There were 20 tumors with no invasion of the choroid and optic nerve (group A) and 23 tumors with invasion of the choroid, optic nerve, and orbit (group B). EpCAM reactivity was correlated with invasion and differentiation of the tumors.

RESULTS. Among the 43 tumors, EpCAM reactivity was observed in 100% (43/43) tumors. EpCAM reactivity was significantly higher in the invasive than the noninvasive tumors (P < 0.05) and in poorly differentiated than in well-differentiated tumors (P < 0.005). Non-neoplastic retina also expressed EpCAM.

CONCLUSIONS. The results confirm that EpCAM is vastly expressed in retinoblastoma and point to its use as a target for therapy in the future.




This article has been cited by other articles:


Home page
 BloodHome page
H. W. Tun, D. Personett, K. A. Baskerville, D. M. Menke, K. A. Jaeckle, P. Kreinest, B. Edenfield, A. C. Zubair, B. P. O'Neill, W. R. Lai, et al.
Pathway analysis of primary central nervous system lymphoma
Blood, March 15, 2008; 111(6): 3200 - 3210.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Association for Research in Vision and Ophthalmology